Yesterday, eMagin Corporation announced that it has commenced a 2-year, $6 million program to develop an ultra-high resolution OLED microdisplay. Managed by the Telemedicine and Advanced Technology Research Center of the US Army Medical Research and Materiel Command, the program introduces the third phase of a multiple year effort to provide a prototype of an ultra-high resolution display system suitable for several applications within Army medicine and military simulation and training.

The Widescreen Ultra eXtended Graphics Array (WUXGA) microdisplay will be sized for a less than one-inch diagonal with over 7 million pixels at a 9.6 micron color pixel pitch. The program involves optic design for a wide field-of-view between 60 and 80 degrees.

Currently, eMagin’s OLED microdisplays already meet military specifications across diverse applications, including IR night vision and tactical situational awareness HMDs, in addition to being integrated into commercial devices such as thermal video cameras and video gaming systems.

Susan

DrStockPick.com Stock Report!

Tuesday September 15, 2009

**************************************************************

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon’s fourth drug candidate currently being tested in Phase 2 clinical trials.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT),

eMagin Corporation, a leading player in OLED microdisplay technology, today announced its preliminary fourth quarter and full-year results for 2008, still subject to independent audit. The company anticipates increases across the board, fueled by enhanced sales efforts.

“Through ongoing cost reduction efforts, improvements in our production processes and growth in sales, we have been able to substantially improve our performance,” Andrew G. Sculley, eMagin’s CEO and president stated in the press release.

eMagin anticipates report revenues for the quarter at $5.3 million, up 13.5 percent from the fourth quarter of last year. Fiscal 2008 revenues are expected at $18.7 million, up 7 percent from the prior year.

The company expects gross margin at 51 percent of revenues, as compared to the 24 percent announced last year. Full year gross margin is expected at 43% of revenues, a significant leap from the 28 percent announced for 2007.

eMagin expects fourth-quarter net income at